服药前后草酸钙结石患者尿微晶的性质变化

采用X射线衍射(XRD)、傅里叶变换红外光谱(FTIR)、纳米粒度仪和透射电子显微镜(TEM)研究了6例草酸钙结石患者在服药前后尿微晶性质的变化.结果表明,服药后尿pH值由服药前的5.87±0.51增加至6.23±0.74;服药前的主要成分为尿酸、一水草酸钙(COM)和磷酸氢盐,服药后尿微晶种类和数量均比服药前减少;服药前,尿微晶的平均粒径为(579±326) nm,服药后减小至(404±338) nm;服药前尿微晶的Zeta电位为(-4.28±2.55) mV,服药后为(-7.29±4.16) mV,Zeta电位变负有利于防止尿微晶沉积;服药前尿微品棱角尖锐,有明显的团聚现象,而服药后尿微晶形貌圆钝,团聚较少.采用现代仪器分析研究服药前后草酸钙结石患者尿液微晶的性质变化,对临床上预防和治疗尿结石具有重要的临床意义.

The property changes of urine crystallites of calcium oxalate stone formers before and after taking medicine

The property changes of urine crystallites of six cases of calcium oxalate stone formers before and after taking medicine were comparatively studied using X-ray diffraction (XRD), Fourier transform infrared (FTIR) spectroscopy, nanoparticle size analyzer, and transmission electron microscopy (TEM). The results showed that the urinary pH increases after taking medicine (before taking 5.87 +/- 0.51, after taking 6.23 +/- 0.74.) Before taking medicine the main components of urine crystallites were uric acid, calcium oxalate monohydrate (COM) and biphosphate. The types and quantities of urine crystallites after taking medicine were less than that of before. The average size of urine crystallite before taking medicine was (579 +/- 326) nm, and it reduced to (404 +/- 338) nm after taking medicine. After taking medicine the zeta potential was also decreased to (-7.29 +/- 4.16) mV from (-4.28 +/- 2.55) mV. The decrease in zeta potential is beneficial to preventing urinary crystallites deposition. The edges and corners of urine crystallite were sharp with significant aggregation before taking medicine, while they became blunt and less aggregation after taking medicine. The analysis of the property changes of urine crystallites of calcium oxalate stone patients before and after taking medicine by using modern equipments has important clinical significance to the clinical prevention and treatment of urinary stones.